Zhi-Hong Jian and Jing-Yang Huang contributed equally to this work.
The authors declare that they have no competing interests.
ZHJ, YPL, and MFW conceived and designed the study. JYH, CCH, and CCL performed the experiments. ZHJ, JYH, CCH, and HHP analyzed the data. JYH and CCL contributed analysis tools. ONN, FCFL, WYK, KMJ, and YCL provided critical inputs on design, analysis, and interpretation of the study. ZHJ and JYH drafted the initial manuscript. All the authors had access to the data. All authors read and approved the final manuscript as submitted.
Asthma and COPD (chronic obstructive pulmonary disease) lead to persistent airway inflammation and are associated with lung cancer. The objective of the study was to assess the relationship between inhaled (ICS) and oral corticosteroid (OCS) use, and risk of lung squamous cell carcinoma (SqCC).
This study was a nested case–control study. Patients with newly diagnosed asthma or COPD between 2003 and 2010 were identified from the National Health Insurance Database. Cases were defined as patients diagnosed with SqCC after enrollment. For each case, four control individuals who were randomly matched for sex and age and date diagnosis of asthma or COPD were selected.
From the 1,672,455 eligible participants, 793 patients with SqCC were matched with 3,172 controls. The odds ratios (ORs) of SqCC in men who received high and low-dose ICS were 2.18 (95 %CI, 1.56–3.04) and 1.77 (1.22–2.57), respectively. Similarly, the ORs were 1.46 (95 %CI, 1.16–1.84) and 1.55 (95 %CI, 1.22–1.98) for men who were placed on low and high dose OCS. However, there was no significant association between cumulative ICS and/or OCS and risk of SqCC in women. Recent dose increase in corticosteriod was significantly associated with risk of SqCC. Specifically, among men, the ORs for SqCC were 8.08 (95 %CI, 3.22–20.30) for high-dose ICS + OCS, 4.49 (95 % CI, 2.05–9.85) for high-dose ICS, and 3.54 (95 % CI, 2.50–5.01) for high-dose OCS treatments, respectively. The OR for SqCC in women who received high-dose OCS was 6.72 (95 %CI, 2.69–16.81).
Corticosteroid use did not decrease SqCC in patients with asthma or COPD. Recent dose increase in corticosteroids was associated with SqCC.
Bentley AM, Hamid Q, Robinson DS, Schotman E, Meng Q, Assoufi B, et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med. 1996;153:551–6. CrossRefPubMed
World Health Oragnization. WHO Collaborating Centre for Drugs Statistics Methodology: ATC/DDD Index 2015. http://www.whocc.no/atc_ddd_index/ (2015). Accessed 24 Apr 2015.
Williams SG, Schmidt DK, Redd SC, Storms W. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. MMWR Recomm Rep. 2003;52(Rr-6):1–8. PubMed
Gundisch S, Boeckeler E, Behrends U, Amtmann E, Ehrhardt H, Jeremias I. Glucocorticoids augment survival and proliferation of tumor cells. Anticancer Res. 2012;32:4251–61. PubMed
Neal RD, Robbe IJ, Lewis M, Williamson I, Hanson J. The complexity and difficulty of diagnosing lung cancer: findings from a national primary-care study in Wales. Prim Health Care Res Dev. 2015;16:436-49.
Tsai YW, Tsai TI, Yang CL, Kuo KN. Gender differences in smoking behaviors in an Asian population. J Womens Health. 2008;17:971–8. CrossRef
Caracta CF. Gender differences in pulmonary disease. Mt Sinai J Med. 2003;70:215–24. PubMed
- The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous cell carcinoma
Frank Cheau-Feng Lin
Oswald Ndi Nfor
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II